Eric Rosenberg, DO
Ophthalmology · New York, NYNPI 1194164186
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Alcon at 35.4% of the total. 2025 is the largest year on record at $145,950, more than ten times the $2,208 reported in 2019. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 758 payments — averaging $571.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$154K
- Tarsus Pharmaceuticals, Inc.$140K
- Alcon Research LLC$60K
- AbbVie$35K
- Glaukos Corporation$10K
- Beaver-visitec International, Inc.$6K
- plus $30K from 28 others
Across 6 payments — averaging $15,464 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$84K
- Oyster Point Pharma, Inc.$8K
What the payments were for
- Consulting fees$158,12136%
- Speaking & faculty fees$226,80052%
- Travel & lodging$21,9775%
- Food & beverage$22,7725%
- Education$3,8981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$132,357
- NGENUITY$103,358
- TRYPTYR$55,240
- Luxor$42,763
- VUITY$31,646
- Clareon$7,862
- AcrySof IQ PanOptix UV IOL$7,723
- Travoprost Intraocular Implant - iDose$7,454
- Ahmed Glaucoma Valve$3,787
- Kahook Dual Blade$3,787
- ARTEVO 800$3,524
- VERACITY SURGICAL$2,974
- AcrySof IQ PanOptix$2,800
- IOLMaster 700$1,980
- Streamline Surgical System$1,787
- Zerviate$1,660
- TearCare SmartLid$1,606
- TEARCARE(TM) (2.2) SYSTEM KIT$1,606
- OMIDRIA$1,564
- Centurion$1,546
How this compares
$433,568 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 160 | $223,928 |
| XdemvyLotilaner | 42 | $75,378 |
| RestasisCyclosporine | 65 | $65,333 |
| MieboPerfluorohexyloctane/Pf | 56 | $55,958 |
| Cyclosporine | 38 | $18,830 |
| LumiganBimatoprost | 28 | $13,430 |
| VevyeCyclosporine | 19 | $13,122 |
| Prednisolone Acetate | 438 | $12,839 |
| TyrvayaVarenicline Tartrate | 16 | $10,013 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $8,564 |
| Alphagan PBrimonidine Tartrate | 18 | $7,423 |
| Ketorolac Tromethamine | 435 | $6,928 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 30 | $5,620 |
| Ofloxacin | 491 | $5,071 |
| Latanoprost | 303 | $2,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $3,114 | $279,886216 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $35,484 | $94,751143 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $139,591 | $75,37842 claims |
| Harrow Eye, LLCVevye | $1,276 | $13,12219 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $869 | $10,01316 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $32 | $2,61115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
- Joshua KimNew York$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.